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Nebulization Therapy
in the Foal
by Cheri Holmberg Rhodes, DVM*
Roger M. Genetzky, DVM, MS, PhD* *
Summary
Bronchopneun10nia was diagnosed in a
Morgan colt with signs of labored respiration,
coughing and bilateral nasal discharge. The
diagnosis was confirmed by auscultation,
radiology and a tracheal wash. Treatment
consisted of antibiotics and nebulization
therapy. In this report, nebulization therapy
will be reviewed.
Case Report
A six-month-old Morgan colt was presented
to the Iowa State Clinics on October 9, 1981.
The animal had a history of coughing, labored
breathing, and bilateral nasal discharge of two
months' duration. He had been treated with
gentamicin, chloramphenicol, penicillin, an-
tihistamines, and D.MSO with little success.
Upon physical examination, the animal ex-
hibited, an expiratory push. The respiratory
rate was thirty five; the temperature and pulse
were normal. Auscultation revealed increased
bronchovesicular sounds over the entire lung
field. An expiratory wheeze was heard over the
tracheal bifurcation and increased friction and
bronchial sounds over the right lower
quadrant of the lung field. A bilateral nasal
discharge was also present.
Radiographic examination of the guttural
pouches appeared normal. In the chest films,
the density of the ventral caudal lung field was
increased, suggesting some consolidation in
the tip of these lobes. The appearance was con-
sistent with an inflammatory response in the
lung. There was no evidence of focal
abscessation.
A CBC was taken and found to be within
normal limits. Fecal flotation revealed Oxyuris
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equi) Parascaris equorum and strongyloid-type
eggs.
A tracheal wash was obtained and
bacteriology yielded a few colonies of gram
negative rods. No significant nurnber of
bacteria were seen on direct cytologic ex=
amination but many neutrophils, macro-
phages and debris indicative of a suppurative
reaction were present. Mesothelial cells,
neutrophils and macrophages were found in
the cytological examination of fluid derived
from a thoracocentesis.
Bronchopneumonia was the tentative
diagnosis and the colt was started on chloram-
phenicol at a dosage of 25 mg/# B.I.D.
Fenbendazole was used to worm the foal. The
foal was nebulized 15 minutes twice a day for
10 days and then the treatment was cut back to
once a day for 5 more days.
To nebulize the foal, a plastic bag was
placed over his head and tubing was placed in-
side the bag. The tubing was connected to a
jet-type nebulizer which was adapted to hook
onto an oxygen tank via a Hudsona demand
value.
The nebulizer ingredients included: 10cc of
Mucomyst~b 20 cc of Bronkosol~-c 10 cc of
gentamicin and 50 cc of saline. Two days after
the initial treatment, the mucopurulent nasal
secretions subsided. By the end of the first
week the lung sounds cleared, and 2 Y2 weeks
after therapy was initiated, the foal was sent
home with no evidence of a respiratory
infection.
aHudson, Hudson Supplies Book Brothers, P.O. Box
834, Fort Dodge, Ia 50501
bMucomystR-(N-acetylcysteine) Mead Johnson &
Company, Evansville, Indiana 47721.
C BronkosoIR-(Isoetharine hydrochloride inhalation,
USP, 1.0%) Breon Laboratories Inc., Mfg by Sterling
Drug Inc., New York, N.Y. 10016.
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Literature Review
The development of aerosol therapy as an
approach to the treatment of respiratory
disease in veterinary medicine has been a slow
process. Inhalants have been used for many
years in human medicine as an adjunct to the
treatment of respiratory disease. An increased
interest in their use has been seen recently due
to the fact that pneumonia of gram negative
etiology has not been treated successfully by
current therapy technique. 17 Furthermore, the
discovery that several antibiotics such as
kanamycin and gentamicin are poorly absorb-
ed from the lungs suggests that these agents
might remain in the lungs for long periods of
time following therapy. 11,16 Thus, the frequen-
cy of therapy could be reduced, as could the
possibility of toxic reactions such as renal
damage associated with parenteral adminis-
tration. These advantages are beginning to
catch the attention of veterinary practitioners.
Little is known about aerosol therapy in
horses. According to Beech, 95 percent of the
aerosol is deposited in the nose of man with
nasal breathing and the percentage is even
higher in horses because of their anatomy.3
Extensive turbinates, large surface area, and
bends in the nasal passage tend to increase
deposition by impact. To bypass the nose and
turbinates when nebulizing human patients,
mouth breathing or pharyngeal tubes may be
used. This increases the probability of particle
deposition in the lungs; unfortunately this is
not possible in horses.
An aerosol is a suspension of particulate
matter in a high speed stream of gas. An
aerosol generator produces an unrefined spray
of particles of random size. A nebulizer refines
the spray by the use of buffers to produce an
aerosol of a select size range. 4
Several factors are important in influencing
aerosol distribution and absorption. These in-
clude: particle size, method of administration,
patency of the airway, duration ofcontact, and
finally, the chemical nature of the drug itself. 5
The number one factor determining deposi-
tion of the inhalant is the droplet size. Larger
particles tend to rain out or be deposited in the
upper airway; and if the particles are too small
and light, the rate of fall is very slow and they
enter and leave the lungs without raining out.
In human medicine the range for deposition of
a drug in the periphery of the lungs is approx-
imately 0.5 microns to 4 microns. Deposition
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in the bronchioles occurs at about 4 microns to
10 microns; in the larger bronchi, at approx-
imately 10 microns to 20 microns; and finally
above 40 microns, most of the deposition oc-
curs in the upper airways.5,19 In horses, par-
ticles less than 3 microns in diameter are ex-
pired, and those larger than 8 microns are re-
moved by the nasopharynx. 3,20
There are 3 basic types of aerosol produc-
tion methods. The first type is a jet-type
nebulizer. According to the laws of physics,4
gas passing through a constriction will have an
increased velocity and a decreased lateral
pressure. A capillary tube at a 90 degree angle
to the constriction, which has one end
submerged in a liquid, will experience a
pressure gradient from liquid to airstream.
The resultant fluid entrapment produces a
coarse spray, which may be directed into a
firm surface, or bafRe, that reduces the larger
particulate output. The second type of aerosol
production is via centrifugal aerosol
generators. 4 A rapidly spinning disk throws
liquid against a baffle at the outer radius of the
disk, breaking it into random-size particles.
The third and most popular type of aerosol
production method is the ultrasonic nebul-
izer. 4 Ultra high-frequency sound waves are
transmitted to a liquid via a piezoelectric
transducer. The liquid is fragmented by rapid
volumetric change into a relatively constant
particulate spray. An outside air source
directed across the liquid surface carries away
a high density, stable aerosol.
Another important factor is how the aerosol
that is generated is delivered to the patient.
Humans can breathe through the output cir-
cuit of an aerosol generator directly; or aerosol
may be delivered by placing the patient in a
fog tent, or by using a face hood as a
reservoir. 3,5 Members of the equine species are
limited to the latter, indirect method. A plastic
bag may be placed over the horse's head with
tubing directing the aerosol from the nebulizer
to the inside of the bag. Alternatively, one
could fashion a nose cone out of a variety of
equipment: gallon jugs with the bottoms cut
away, conical-shaped plastic waste baskets
padded with strips of foam, or any other piece
ofequipment that will deliver the nebulized air
in the direction of the nasal passages.9
The patency of the airway is a third factor to
consider. If there is an upper airway obstruc-
tion, it is obvious that the aerosol will be
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deposited proximal to the obstruction. 6
Therefore, it is imperative that a patent airway
be present for aerosol to be deposited in the
periphery of the lung.
Duration of contact also influences aerosol
deposition. In human medicine, patients are
encouraged to take a slow, deep breath and
hold it at the end of inspiration so that maxi-
mum deposition of aerosol will occur. 5 If the
patient is panting, which is often the case in
small animals who are having respiratory
difficulty, it is very hard to get an aerosol down
into the alveoli. Finally, the chemical nature of
the drug itself also influences deposition. 3 •6
It is important to determine where the
aerosol should go when treating a specific pa-
tient. Bronchodilator drugs are used when one
wants the drug to penetrate into smaller bron-
chioles or toward the alveoli. An aerosol
generator should be used that produces a small
droplet size. On the other hand, if one wanted
rain-out to occur in the upper airways to
"superhumidify" secretions, an aerosol
generator that produces a larger-sized particle
should be used. 6
The total dose of drug that is actually ab-
sorbed is also a factor to consider. Droplet size
comes into play here. Although the smaller
particles are deposited more peripherally, the
larger droplets contain more drug; but the
more peripheral the deposition, the greater the
percentage of d:r:-ug that will be absorbed.
Aerosols are used to (1) provide humidifica-
tion; (2) to provide bronchodilatation; (3) to
alter the characteristics of secretions; (4) to
treat infections; and (5) to aid in collecting
specimens. 6
Humidity
When the natural upper airway is by-
passed, as with a tracheostemy, endotracheal
or nasotracheal tube, high density mist or high
humidity in the inspired air is needed to pre-
vent mucus impaction. This is because the pa-
tient's ability to humidify the gases he breathes
is compron1ised. 6.16 Another danger is that the
tracheal mucosa can become dried out and
friable with inadequate moisturization. At
body temperature, the alveolar gas is com-
pletely saturated; a moisture deficit in the
large airways is possible if precautions are not
taken to add adequate moisture to inhaled
gases.
The moisture needed to prevent these com-
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plications is supplied as molecular water (high
humidity) or as particulate water (aerosol).
Many adequate commercial devices are
available for providing these forms of
moisture.
Bronchodilatation
To provide for bronchodilation a drug must
reach the mucosa of the bronchial tree either
systemically or topically. A patent airway is
imperative if you want to get the drug down to
the respiratory bronchiole. The drugs used
can be divided into two general categories:
specific and nonspecific bronchodilators. 6 In
general, the main effects of a bronchodilator
are to relax bronchiole circumferential smooth
muscles; to relax longitudinal smooth muscle
fibers that extend into alveolar ducts and
alveolar sacs and therefore increase com-
pliance; and to shrink mucosa and decrease
secretory activity through vasomotor effects
(decongestant action. )3.8.13.18
Epinephrine and isoproterenol are the
specific bronchodilators most commonly used
in aerosol form. In addition to its bron-
chodilator action, epinephrine is also a
mucosal decongestant. When isoproterenol is
used, constrictors such as phenylephrine are
occasionally added to produce mucosal
decongestion. These sympathomimetics have
potent side effects on the cardiovascular
system which require individualization of
dosage and monitoring of the patient
throughout therapy. Sympathomin1etics work
by increasing phosphorylase activity and they
also stimulate the conversion of ATP to 3,5
AMP. 13 •18
Steroids are used as nonspecific bron-
chodilators. Recent studies have shown that
some patients with asthma, especially
children, can be maintained on lower total
doses of steroids administered by aerosol than
might be required if administered paren-
terally.
BronkosolR is a sympathomimetic amine
with preferential affinity for Beta2 adrenergic
receptor sites of bronchial and certain
arteriolar musculature, and a lower order of
affinity for Betal adrenergeic receptors. It has
a rapid onset of action and a relatively long
duration also. It gives symptomatic relief of
bronchospasm and this aids in significantly in-
creasing vital capacity. Drug interactions are
important and BronkosolR should not be ad-
ministered along with epinephrine or other
Iowa State Veterinarian
sympathomimetic amines SInce these drugs
are direct cardiac stimulants and may cause
excessive tachycardia. They may, however, be
alternated if desired.
Altering Secretions
Aerosols are also used in an attempt to alter
the character of secretions and thus aid in
bronchial evacuation. Specifically, saline or
mucolytic agents in aerosol form are used to
promote bronchial evacuation. The rationale
for this type of therapy can be explained by a
brief review of mucus production and function
in the respiratory tract.
The fluid layer covering most of the
respiratory tract epithelium consists of a
serous watery liquid in which cilia from the
epithelial cells protrude, overlain by the
mucus layer. 3The properties of mucus depend
on the glycoproteins around which water is
organized and bound. 2 .20 The viscosity of
mucus, for example, is determined by the in-
tramolecular binding of the glycoproteins.
Mucoid sputum, white, adhesive, and
gelatinous, is more viscid than is purulent
sputum. Mucoid sputum becomes less viscid
with the addition of water, and as it dries
viscosity increases. With purulence there is in-
creased cross-linkage of glycoproteins by
disulfide bonds, and these bonds differ in
cleavage properties. 20 Purulent sputum is
thick, opaque, and yellow; it is less viscid than
is mucoid sputum and contains DNA fibers
originating from degenerated white cells. Its
vicosity is decreased by pancreatic dornase
(streptokinase and deoxyribonuclease). 2. 7.20
Acetylcysteine, pancreatic dornase, ascox-
aI, trypsin, chymotrypsin, potassium chloride,
potassium iodide and buffered L-arginine are
common mucolytic agents.2.10.13.14.15.21 How-
ever, bronchospasm and bronchial edema are
side effects of mucolytic agents because they
can be irritating to mucus membranes. 14.15.20
Detergents or wetting agents are also used to
decrease surface tension and viscosity of
sputum. Alevaire~d a solution with the
detergent superinone, is effective in man and
has been used in horses. 2 Controlled trials in
laboratory animals, however, show that it is no
more effective than water. 14,20
MucomystR (N-acetylcysteine) works by
breaking up the polysaccaride bonds of n1ucin
and therefore is classified as a specific
d Alevaire-Breon Laboratory, 90 Park Avenue, New
York, N.Y. 10016.
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mucolytic agent. 6 Irritation of the airway
mucosa is seen in some patients with a history
of bronchospastic disease due to this drug,
therefore the simultaneous use of a bron-
chodilating agent is necessary. Acetylcysteine
has no effect on blood, fibrin, or pus. A related
compound, methylcysteine hydrochloride,
decreases bronchial secretions. 2
Treating Infections
Although most medical personnel feel that
antibiotics are best given by injection, aerosols
of antibiotics have been used to treat infection.
Antibiotic aerosols have been recommended
when the antibiotic for the specific organism
cultured cannot be given systemically because
of its toxicity. Aerosols have also been recom-
n1ended for use in patients who may have in-
trapulmonary disease that is walled off from
the circulation. 6 ,12,20
Antibiotics absorbed poorly or not at all in
aerosol form include neomycin, kanamycin,
gentamicin, polymixin B, bacitracin, and the
antifungal drugs nystatin and amphotericin
B. 2 To be effective, these drugs must be de-
posited over a large area of the lung. This is
because their effectiveness depends on the mi-
croorganisms being on the surface and the
drugs not being inactivated by DNA or other
material in the exudate.
Kanamycin is well tolerated but only a small
portion is deposited in the lower respiratory
tract. 9.11,20 Studies have shown that aerosols of
kanamycin can be used effectively to treat
pneumonia in rats, mice, and monkeys.17.
The efficacy of kanamycin aerosols seems to
result from persistance of drug in the lung, an
observation that may have great importance
for patients with impaired kidney function.
The use of aerosol therapy seems to almost
completely circumvent the problem of renal
toxicity associated with kanamycin.
Gentamicin nebulized in laboratory rats
results in high concentrations throughout the
respiratory tract, but low serum levels. 2
Carbenicillin and related agents are incom-
patible with acetylcysteine. 2
In cattle, nebulization of penicillin, strep-
tomycin, and antihistamine combinations is
no more effective than is systemic administra-
tion of the same drugs in treating bacterial
bronchopneumonia. 1
Discussion
Familiarity with drugs, their assets and their
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disadvantages, and the opportunity to
medicate the patient properly will play a role
in determining how successful nebulization
will be as an adjunct to therapy in respiratory
disease. When using aerosols one should
always think in terms of why the drug is given,
how the drug is administered, and what the
side effects of aerosol therapy can be.
Aerosols can be a very valuable therapeutic
tool. However, as a word of caution, although
a little bit is good, a lot is not necessarily twice
as good - it may be harmful. An animal can be
drowned by the use of an ultrasonic ne-
bulizer. 6 By continual exposure to high flow,
high density aerosols, the arterial oxygen ten-
sion may progressIvely decrease as the length
of exposure to constant breathing of aerosol
increases. 6 This hypoxia is related to an in-
creasing alveolar- arterial oxygen gradient,
caused by the deposition of fluid in the alveoli,
leading to an intrapulmonary shunt which in-
creases as exposure time progresses. 6
Therefore, hypoxia due to intrapulmonary
shunting from the accumulation of fluid is a
possible complication with the use of aerosols.
Thus, it is important not to routinely use
aerosols for hours on end, unless the amount
delivered to the patient is constantly
monitored and controlled.
Another danger is the possibility of bacterial
growth within the nebulizer. 16 Only a sterile
nebulizer should be used. When it needs
refilling, residual water should be discarded,
the container rinsed, and then refilled with
sterile water. Tubing that collects condensa-
tion should also be cleaned rather than drained
back into the reservoir because it may contain
contaminating bacteria.
In conclusion, the future of aerosol therapy
in veterinary medicine depends on research
findings, practicality, availability, early ac-
curate diagnosis, knowledge of disease patho-
genesis and the pharmacologic basis of
therapy. Aerosol therapy should be used but
not abused. 6
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